|
|
Article: House Subcommittee Hearing Debates SBIR Eligibility Rules.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
WASHINGTON - A pair of biotech execs addressed a congressional subcommittee in their fight for an exception to a Small Business Administration rule that precludes their companies from receiving Small Business Innovation Research (SBIR) grants.
"The irony of this is that you have companies that have proven themselves at some level at developing technology for which they've [previously] gotten funding," explained Douglas Doerfler, the president and CEO of MaxCyte Inc., "but now those same companies aren't eligible to help pivotal technologies that are directly in line with what NIH is trying to achieve in its mission."
He spoke ...